# Lakewood-Amedex Biotherapeutics Inc.: financial statements, quarterly

LABT · Nasdaq · CIK 2079272 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/labt.md) · [Financials](/companies/labt/financials.md) · [Filings](/companies/labt/filings.md) · [Insiders](/companies/labt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/labt/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Cost of revenue | $k | not reported | not reported | [507](/filings/0001213900-26-060640.md) | not reported |
| Research and development | $k | [170](/filings/0001213900-26-060640.md) | [147](/filings/0001213900-26-089380.md) | [182](/filings/0001213900-26-060640.md) | [503](/filings/0001213900-26-089380.md) |
| Operating income | $k | [(543)](/filings/0001213900-26-060640.md) | [(637)](/filings/0001213900-26-089380.md) | [(887)](/filings/0001213900-26-060640.md) | [(3,790)](/filings/0001213900-26-089380.md) |
| Interest expense | $k | [1.3](/filings/0001213900-26-060640.md) | [23.9](/filings/0001213900-26-089380.md) | [38.2](/filings/0001213900-26-060640.md) | [10.6](/filings/0001213900-26-089380.md) |
| Net income | $k | [(540)](/filings/0001213900-26-089380.md) | [(656)](/filings/0001213900-26-089380.md) | [(923)](/filings/0001213900-26-089380.md) | [(3,772)](/filings/0001213900-26-089380.md) |
| Diluted EPS | $ per share | [(0.15)](/filings/0001213900-26-060640.md) | [(1.66)](/filings/0001213900-26-089380.md) | [(0.20)](/filings/0001213900-26-060640.md) | [(2.75)](/filings/0001213900-26-089380.md) |
| Basic EPS | $ per share | [(0.15)](/filings/0001213900-26-060640.md) | [(1.66)](/filings/0001213900-26-089380.md) | [(0.20)](/filings/0001213900-26-060640.md) | [(2.75)](/filings/0001213900-26-089380.md) |

- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | period not labelled (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $k | not reported | not reported | not reported | [236](/filings/0001213900-26-089380.md) | [11.7](/filings/0001213900-26-060640.md) | [2,585](/filings/0001213900-26-089380.md) |
| Current assets | $k | not reported | not reported | not reported | [305](/filings/0001213900-26-089380.md) | [50.6](/filings/0001213900-26-060640.md) | [4,845](/filings/0001213900-26-089380.md) |
| Total assets | $k | not reported | not reported | not reported | [482](/filings/0001213900-26-089380.md) | [196](/filings/0001213900-26-060640.md) | [4,960](/filings/0001213900-26-089380.md) |
| Current liabilities | $k | not reported | not reported | not reported | [2,405](/filings/0001213900-26-089380.md) | [3,028](/filings/0001213900-26-060640.md) | [629](/filings/0001213900-26-089380.md) |
| Total liabilities | $k | not reported | not reported | not reported | [2,446](/filings/0001213900-26-089380.md) | [3,038](/filings/0001213900-26-060640.md) | [629](/filings/0001213900-26-089380.md) |
| Shareholders' equity | $k | [410](/filings/0001213900-26-089380.md) | [(76.2)](/filings/0001213900-26-089380.md) | [(683)](/filings/0001213900-26-089380.md) | [(1,965)](/filings/0001213900-26-089380.md) | [(2,842)](/filings/0001213900-26-089380.md) | [4,331](/filings/0001213900-26-089380.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(404)](/filings/0001213900-26-060640.md) | [(509) d](/filings/0001213900-26-089380.md) | [(350)](/filings/0001213900-26-060640.md) | [(2,104) d](/filings/0001213900-26-089380.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

## Shares

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [6,943](/filings/0001213900-26-060640.md) | [694](/filings/0001213900-26-089380.md) | [6,995](/filings/0001213900-26-060640.md) | [1,420](/filings/0001213900-26-089380.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 2,369,688 at 2026-08-03, from the cover of the [10-Q filed 2026-08-14](/filings/0001213900-26-089380.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.